Technology

Our disruptive technology delivers a soluble, fast acting powder-form drug formulation which has been developed by using our patented methodology, and “trade secret” process.

Aspire’s sublingual dose form avoids some harmful side effects of various drug therapies while maintaining or enhancing benefits. These results come from a new mechanism of action (absorption pathway) which allows for rapid sublingual absorption in the mouth.

The speed of absorption and level of absorption due to our new mechanism of action into the blood stream is significant. Aspire’s sublingual dose form avoids some harmful side effects of various drug therapies while maintaining or enhancing benefits. It avoids direct damage to mucus secreting Goblet cells lining the GI track and avoids bioavailability reduction by first pass hepatic metabolism.

Aspire formula

Fast Acting
Powder-form medication developed using our patented formula

Perfects Dosage Management
Drugs do not pass through the liver and are not
metabolized

Bypasses the Digestive Tract
Eliminates adverse reactions in the gastrointestinal tract

Sublingual Aspirin Product
Our first sublingual aspirin product is soon to be released to the public.

Our technology can be applied to any number of proven drugs and supplements. The list below are just a few examples, but there are undoubtedly many more.

- Analgesics – global analgesics market (including Opioids) valued approximately $77.0 billion in 2021 and is projected to grow at a 5% CAGR and reach to roughly $103.0 billion by 2028

- Erectile Dysfunction (ED) – global ED market valued approximately $3.6 billion in 2021 and is projected to grow at a 6.9% CAGR and reach to roughly $5.9 billion by 2028

- Caffeine Pre-Workout – global pre-workout market value at approximately $19.58 billion in 2024 and growing.

Aspire Biopharma, Inc. has developed a disruptive technology that is a Novel Soluble Formulation, which addresses emergencies, drug efficacy, dosage management, and response time.

Aspire’s launch product, the sublingual aspirin product, will be an aspirin formulation which addresses cardiology and stroke emergencies, acute pain management and anti-inflammatory needs.

Benefits of “instant absorption” aspirin are: to stop heart attack and stroke; allow high-dose absorption for pain management, including quick headache relief, post-surgery, cancer pain management, and general pain relief.

The sublingual aspirin product is also targeted to be a safe and effective Opioid alternative.

Aspire’s sublingual aspirin product is currently in clinical trials. We hope to file our 505(b)(2) application with the FDA in July 2025, seeking fast-track approval.